Friday 16 October 2026
Export ZNTL’s income statement to Excel — free account
Zentalis Pharmaceuticals, Inc.
ZNTL Healthcare Biotechnology
Zentalis Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $67.4 million. In the quarter to June 2026, EPS fell 59.5% and free cash flow fell 9.06%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.13
0.11
−4.91%
Follow ZNTL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
7.55 | 6.73 | 6.01 | 4.64 | |
Current Ratio |
7.76 | 6.93 | 6.19 | 4.82 | |
Net Debt/EBITDA |
8.23 | 6.53 | 5.58 | 3.94 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.01 | 0.88 | 0.93 | 0.88 | |
Capex/Depreciation |
0.00 | (0.47) | 0.47 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.37) | (0.43) | (0.47) | (0.52) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.37) | (0.43) | (0.47) | (0.52) | |
Cash per Share |
3.89 | 3.42 | 3.01 | 2.45 | |
Shareholders Equity per Share |
3.51 | 3.01 | 2.60 | 2.01 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.51 | 3.01 | 2.60 | 2.01 | |
Free Cash Flow |
(26.96) | (30.81) | (32.99) | (37.24) | |
Working Capital |
251.13 | 216.63 | 182.86 | 143.65 | |
Capital Expenditures |
0.00 | 0.13 | (0.03) | 0.00 | |
Net Current Asset Value |
213.93 | 180.43 | 147.71 | 109.60 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
7.62 | 7.32 | 7.57 | 5.93 | |
Average Assets |
388.96 | 359.65 | 318.54 | 283.52 | |
Average Common Equity |
303.60 | 276.70 | 239.03 | 209.07 |
Columns are period end dates